Goldman Sachs
ACAD icon

Goldman Sachs’s Acadia Pharmaceuticals ACAD Stock Holding History

Goldman Sachs’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-89,800
Closed -$1.92M – 6412
2025
Q3 		$1.92M Hold
89,800
– – ﹤0.01% 4525
2025
Q2 		$1.94M Hold
89,800
– – ﹤0.01% 4208
2025
Q1 		$1.49M Hold
89,800
– – ﹤0.01% 4382
2024
Q4 		$1.65M Hold
89,800
– – ﹤0.01% 4455
2024
Q3 		$1.38M Hold
89,800
– – ﹤0.01% 4418
2024
Q2 		$1.46M Buy
+89,800
New +$1.45M ﹤0.01% 4173
2020
Q4 		– Sell
-31,900
Closed -$1.32M – 5449
2020
Q3 		$1.32M Buy
31,900
+11,900
+60% +$514K ﹤0.01% 3880
2020
Q2 		$969K Sell
20,000
-54,500
-73% -$2.62M ﹤0.01% 3975
2020
Q1 		$3.15M Buy
+74,500
New +$3.07M ﹤0.01% 2992
2019
Q2 		– Sell
-12,700
Closed -$341K – 5096
2019
Q1 		$341K Buy
+12,700
New +$297K ﹤0.01% 4574
2017
Q4 		– Sell
-50,000
Closed -$1.88M – 6296
2017
Q3 		$1.88M Buy
+50,000
New +$1.63M ﹤0.01% 4054
2016
Q4 		– Sell
-100,000
Closed -$3.18M – 6865
2016
Q3 		$3.18M Buy
+100,000
New +$3.39M ﹤0.01% 3424
2016
Q2 		– Sell
-398,000
Closed -$11.1M – 7002
2016
Q1 		$11.1M Buy
398,000
+348,000
+696% +$7.59M ﹤0.01% 2134
2015
Q4 		$1.78M Hold
50,000
– – ﹤0.01% 3739
2015
Q3 		$1.65M Sell
50,000
-139,700
-74% -$5.81M ﹤0.01% 3988
2015
Q2 		$7.95M Hold
189,700
– – ﹤0.01% 2538
2015
Q1 		$6.18M Sell
189,700
-1,221,900
-87% -$42M ﹤0.01% 2700
2014
Q4 		$44.8M Sell
1,411,600
-1,737,400
-55% -$49.3M 0.01% 1197
2014
Q3 		$78M Hold
3,149,000
– – 0.02% 774
2014
Q2 		$71.1M Hold
3,149,000
– – 0.02% 878
2014
Q1 		$76.6M Sell
3,149,000
-212,900
-6% -$5.39M 0.03% 759
2013
Q4 		$84M Buy
3,361,900
+25,000
+0.7% +$590K 0.03% 711
2013
Q3 		$91.7M Hold
3,336,900
– – 0.03% 635
2013
Q2 		$60.6M Buy
+3,336,900
New +$46M 0.02% 795

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Goldman Sachs's ACAD Position: Q2 2026 in Review

Goldman Sachs increased its Acadia Pharmaceuticals (ACAD) stake by 66% in Q2 2026, buying an estimated $22.5M and bringing the position to 2,580,115 shares worth $65.3M. The position accounts for 0.01% of the portfolio, ranked #1581.

Goldman Sachs first reported a position in ACAD in Q2 2013 and has held it in 53 quarters since. The position peaked at $68.6M in Q3 2017. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Goldman Sachs held 2,580,115 shares of Acadia Pharmaceuticals worth $65.3M as of Q2 2026.
  • Goldman Sachs bought 1,022,311 Acadia Pharmaceuticals shares in Q2 2026, an estimated $22.5M.
  • Acadia Pharmaceuticals made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1581 holding.
  • Goldman Sachs first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Goldman Sachs's Acadia Pharmaceuticals position peaked at $68.6M in Q3 2017.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.